MeSH D018783 - vasculogenic impotence
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Tadalafil | Alyq |  | 2019-02-05 |  |  |
| Tadalafil | Tadalafil |  | 2018-05-22 |  |  | |
| Mylan | Tadalafil | Tadalafil |  | 2018-08-03 |  |  |
| Tadalafil | Tadalafil Mylan |  | 2014-11-21 |  |  | |
| Cipla | Tadalafil | Tadalafil |  | 2019-03-26 |  |  |
| Lupin Research | Tadalafil | Tadalafil |  | 2019-03-26 |  |  |
| Chartwell Pharmaceuticals | Tadalafil | Tadalafil |  | 2019-02-05 |  |  |
| Pfizer | Alprostadil | Caverject |  | 1995-07-06 |  |  |
| Alprostadil | Prostin |  | 1982-01-01 |  |  |
1
2
3
4
5
6
7
>
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
100%1/1
Phase 3
80%4/5
Approved: 4Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use